225 related articles for article (PubMed ID: 26458958)
1. Evaluation of an epithelial plasticity biomarker panel in men with localized prostate cancer.
Armstrong AJ; Healy P; Halabi S; Vollmer R; Lark A; Kemeny G; Ware K; Freedland SJ
Prostate Cancer Prostatic Dis; 2016 Mar; 19(1):40-5. PubMed ID: 26458958
[TBL] [Abstract][Full Text] [Related]
2. Comprehensive study of gene and microRNA expression related to epithelial-mesenchymal transition in prostate cancer.
Katz B; Reis ST; Viana NI; Morais DR; Moura CM; Dip N; Silva IA; Iscaife A; Srougi M; Leite KR
PLoS One; 2014; 9(11):e113700. PubMed ID: 25409297
[TBL] [Abstract][Full Text] [Related]
3. MiR-301a regulates E-cadherin expression and is predictive of prostate cancer recurrence.
Nam RK; Benatar T; Wallis CJ; Amemiya Y; Yang W; Garbens A; Naeim M; Sherman C; Sugar L; Seth A
Prostate; 2016 Jul; 76(10):869-84. PubMed ID: 26990571
[TBL] [Abstract][Full Text] [Related]
4. Mesenchymal phenotype after chemotherapy is associated with chemoresistance and poor clinical outcome in esophageal cancer.
Hara J; Miyata H; Yamasaki M; Sugimura K; Takahashi T; Kurokawa Y; Nakajima K; Takiguchi S; Mori M; Doki Y
Oncol Rep; 2014 Feb; 31(2):589-96. PubMed ID: 24297447
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of Akt activity induces the mesenchymal-to-epithelial reverting transition with restoring E-cadherin expression in KB and KOSCC-25B oral squamous cell carcinoma cells.
Hong KO; Kim JH; Hong JS; Yoon HJ; Lee JI; Hong SP; Hong SD
J Exp Clin Cancer Res; 2009 Feb; 28(1):28. PubMed ID: 19243631
[TBL] [Abstract][Full Text] [Related]
6. The epithelial-mesenchymal transition regulators Twist, Slug, and Snail are associated with aggressive tumour features and poor outcome in prostate cancer patients.
Børretzen A; Gravdal K; Haukaas SA; Mannelqvist M; Beisland C; Akslen LA; Halvorsen OJ
J Pathol Clin Res; 2021 May; 7(3):253-270. PubMed ID: 33605548
[TBL] [Abstract][Full Text] [Related]
7. Akt Activation Correlates with Snail Expression and Potentially Determines the Recurrence of Prostate Cancer in Patients at Stage T2 after a Radical Prostatectomy.
Chen WY; Hua KT; Lee WJ; Lin YW; Liu YN; Chen CL; Wen YC; Chien MH
Int J Mol Sci; 2016 Jul; 17(8):. PubMed ID: 27455254
[TBL] [Abstract][Full Text] [Related]
8. Impact of positive surgical margins on prostate-specific antigen failure after radical prostatectomy in adjuvant treatment-naïve patients.
Ploussard G; Agamy MA; Alenda O; Allory Y; Mouracade P; Vordos D; Hoznek A; Abbou CC; de la Taille A; Salomon L
BJU Int; 2011 Jun; 107(11):1748-54. PubMed ID: 20883488
[TBL] [Abstract][Full Text] [Related]
9. Epithelial-Mesenchymal Transition Markers β-catenin, Snail, and E-Cadherin do not Predict Disease Free Survival in Prostate Adenocarcinoma: a Prospective Study.
Ipekci T; Ozden F; Unal B; Saygin C; Uzunaslan D; Ates E
Pathol Oncol Res; 2015 Sep; 21(4):1209-16. PubMed ID: 26037169
[TBL] [Abstract][Full Text] [Related]
10. Co-expression of SNAIL and TWIST determines prognosis in estrogen receptor-positive early breast cancer patients.
van Nes JG; de Kruijf EM; Putter H; Faratian D; Munro A; Campbell F; Smit VT; Liefers GJ; Kuppen PJ; van de Velde CJ; Bartlett JM
Breast Cancer Res Treat; 2012 May; 133(1):49-59. PubMed ID: 21796367
[TBL] [Abstract][Full Text] [Related]
11. ABCG2/BCRP gene expression is related to epithelial-mesenchymal transition inducer genes in a papillary thyroid carcinoma cell line (TPC-1).
Mato E; González C; Moral A; Pérez JI; Bell O; Lerma E; de Leiva A
J Mol Endocrinol; 2014 Jun; 52(3):289-300. PubMed ID: 24643400
[TBL] [Abstract][Full Text] [Related]
12. Utility of tissue microarrays for profiling prognostic biomarkers in clinically localized prostate cancer: the expression of BCL-2, E-cadherin, Ki-67 and p53 as predictors of biochemical failure after radical prostatectomy with nested control for clinical and pathological risk factors.
Nariculam J; Freeman A; Bott S; Munson P; Cable N; Brookman-Amissah N; Williamson M; Kirby RS; Masters J; Feneley M
Asian J Androl; 2009 Jan; 11(1):109-18. PubMed ID: 19050681
[TBL] [Abstract][Full Text] [Related]
13. Clinical significance of epithelial-mesenchymal transition markers in prostate cancer.
Figiel S; Vasseur C; Bruyere F; Rozet F; Maheo K; Fromont G
Hum Pathol; 2017 Mar; 61():26-32. PubMed ID: 27818287
[TBL] [Abstract][Full Text] [Related]
14. Expression patterns of epithelial-mesenchymal transition markers in localized prostate cancer: significance in clinicopathological outcomes following radical prostatectomy.
Behnsawy HM; Miyake H; Harada K; Fujisawa M
BJU Int; 2013 Jan; 111(1):30-7. PubMed ID: 23107154
[TBL] [Abstract][Full Text] [Related]
15. Clinicopathological significance of Sip1-associated epithelial mesenchymal transition in non-small cell lung cancer progression.
Miura N; Yano T; Shoji F; Kawano D; Takenaka T; Ito K; Morodomi Y; Yoshino I; Maehara Y
Anticancer Res; 2009 Oct; 29(10):4099-106. PubMed ID: 19846957
[TBL] [Abstract][Full Text] [Related]
16. Expression of the transcription factor snail and its target gene twist are associated with malignancy in pheochromocytomas.
Waldmann J; Slater EP; Langer P; Buchholz M; Ramaswamy A; Walz MK; Schmid KW; Feldmann G; Bartsch DK; Fendrich V
Ann Surg Oncol; 2009 Jul; 16(7):1997-2005. PubMed ID: 19412634
[TBL] [Abstract][Full Text] [Related]
17. Epithelial to mesenchymal transition markers are associated with an increased metastatic risk in primary cutaneous squamous cell carcinomas but are attenuated in lymph node metastases.
Toll A; Masferrer E; Hernández-Ruiz ME; Ferrandiz-Pulido C; Yébenes M; Jaka A; Tuneu A; Jucglà A; Gimeno J; Baró T; Casado B; Gandarillas A; Costa I; Mojal S; Peña R; de Herreros AG; García-Patos V; Pujol RM; Hernández-Muñoz I
J Dermatol Sci; 2013 Nov; 72(2):93-102. PubMed ID: 23928229
[TBL] [Abstract][Full Text] [Related]
18. What are the factors associated with short prostate specific antigen doubling time after radical prostatectomy? A report from the SEARCH database group.
Teeter AE; Bañez LL; Presti JC; Aronson WJ; Terris MK; Kane CJ; Amling CL; Freedland SJ;
J Urol; 2008 Nov; 180(5):1980-4; discussion 1985. PubMed ID: 18801519
[TBL] [Abstract][Full Text] [Related]
19. Change in PSA velocity is a predictor of overall survival in men with biochemically-recurrent prostate cancer treated with nonhormonal agents: combined analysis of four phase-2 trials.
Suzman DL; Zhou XC; Zahurak ML; Lin J; Antonarakis ES
Prostate Cancer Prostatic Dis; 2015 Mar; 18(1):49-55. PubMed ID: 25384338
[TBL] [Abstract][Full Text] [Related]
20. PSA doubling time as a predictor of clinical progression after biochemical failure following radical prostatectomy for prostate cancer.
Roberts SG; Blute ML; Bergstralh EJ; Slezak JM; Zincke H
Mayo Clin Proc; 2001 Jun; 76(6):576-81. PubMed ID: 11393495
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
